TL;DR
This paper details the rigorous curation of 31 genes associated with Limb Girdle Muscular Dystrophy (LGMD) by an expert panel. This work establishes a robust, evidence-based framework for understanding gene-disease relationships, crucial for accurate diagnosis and genetic testing in LGMD patients.
What Problem Does This Paper Address?
Limb Girdle Muscular Dystrophy (LGMD) is a group of genetically diverse disorders characterized by progressive weakness in the proximal limb muscles. While advances in sequencing technology have identified numerous genes linked to LGMD, accurately interpreting these findings and establishing definitive gene-disease relationships has been challenging. This lack of clarity hinders precise diagnosis, genetic counseling, and the development of targeted therapies. The paper addresses the need for a standardized, evidence-based approach to validate these gene-disease relationships, moving beyond expert consensus to a systematic, data-driven assessment.
Methods
The core methodology employed is the ClinGen gene-disease clinical validity framework. This framework involves an expert panel (the ClinGen Muscular Dystrophies and Myopathies gene curation expert panel, MDM GCEP) systematically evaluating the strength of evidence supporting a gene-disease relationship (GDR). This evaluation is based on a semi-quantitative scoring system that considers both genetic evidence (e.g., variants identified in patients, family studies) and experimental evidence (e.g., functional studies, animal models). Points are awarded for each piece of evidence, leading to an overall classification of the GDR as Definitive, Strong, Moderate, or Limited. The panel also applied "lumping and splitting" guidelines to determine whether multiple reported disease entities associated with a single gene should be treated as one or separate GDRs, based on phenotypic variability, inheritance patterns, and molecular mechanisms.
Datasets
The paper does not introduce new datasets. Instead, it relies on the systematic review of existing scientific literature, including published case reports, family studies, linkage analyses, and experimental research, to gather evidence for gene-disease relationships. Information from databases like OMIM (Online Mendelian Inheritance in Man) was also utilized.
Key Insights and Ideas
- Systematic Validation is Crucial: The paper highlights the critical need for a standardized, evidence-based approach to validate gene-disease relationships, moving beyond anecdotal evidence or expert opinion.
- LGMD is a Complex Spectrum: The research underscores that LGMD is not a monolithic entity. Many genes implicated in LGMD are also associated with broader myopathic phenotypes, requiring careful consideration of disease spectrum and nomenclature.
- The Power of Expert Consensus: The MDM GCEP's work demonstrates the value of bringing together diverse expertise (clinical, molecular genetics, research) to reach consensus on complex scientific questions.
- The Importance of Re-curation: The re-evaluation of previously classified GDRs shows that scientific understanding evolves, and periodic re-curation is essential to incorporate new evidence and refine classifications.
- Community Engagement is Key: The authors emphasize the need for the broader scientific community to publish case-level data to help clarify disputed or novel LGMD associations.
Key Results
The MDM GCEP evaluated 31 genes, resulting in 35 gene-disease relationships (GDRs).
- Classification Breakdown:
- 30 (86%) were classified as Definitive.
- 4 (11%) were classified as Moderate.
- 1 (3%) was classified as Limited.
- No GDRs were classified as Strong, No Known Disease Relationship, Disputed, or Refuted.
- Gene Splitting: Four genes (CAPN3, COL6A1, COL6A2, COL6A3) were split into separate GDRs due to distinct autosomal dominant and recessive inheritance patterns and pathogenic mechanisms.
- Re-curation Impact: Four GDRs were re-curated, leading to upgrades for DAG1 (Moderate to Definitive) and TNPO3 and POPDC3 (Limited to Moderate). PLEC's classification remained Moderate.
- Collaborative Efforts: Five genes were co-curated with the ClinGen Congenital Myopathies GCEP, with the MDM GCEP acting as a secondary contributor.
Limitations and Future Work
- Insufficient Evidence for Some Genes: The paper notes that while POMGNT1 and DAG1 are definitively related to myopathy, there is currently insufficient evidence to support a specific relationship with LGMD for these genes. The authors urge the community to publish more cases meeting LGMD phenotype criteria with causative variants in these genes.
- Dynamic Nature of Classifications: Non-Definitive classifications (Moderate, Limited) are expected to change over time as new evidence emerges and re-curation efforts are undertaken.
- Future Re-curation: The ClinGen framework recommends re-curating Limited through Strong classifications every 2-3 years. The MDM GCEP plans to re-evaluate Moderate and Limited relationships and assess any additional or novel genes related to LGMD.
- Standardization of Testing: The authors highlight the ongoing need for systematic evaluation of GDRs to standardize genes included in genetic tests for LGMD and related phenotypes.
- New Gene Identification: Since the inception of the MDM GCEP, three new LGMD genes (JAG2, HMGCR, and SNUPN) have been published, indicating the continuous discovery in this field.
Summary updated